6月25日，Guardant Health盘中上涨5.05%，报143.31美元/股，成交额7875.13万美元。
消息面上，RBC Capital Markets于6月12日首次覆盖并给予"跑赢大盘"评级及185美元目标价，指出美国仅约25%的转移性癌症患者接受基因组分析，公司作为市场领导者最受益于行业渗透扩大。此外，6月11日Guardant360 CDx获FDA批准作为非小细胞肺癌伴随诊断，叠加一季度业绩大超预期（调整后EPS为-0.45美元，好于预期的-0.76美元）及全年收入指引上调至13.0亿-13.2亿美元，多重催化共振推动股价延续强势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.